What Is Placental Malaria and Its Dangers?

Placental malaria is a condition in which malaria parasites accumulate inside the placenta during pregnancy, triggering inflammation and tissue damage that can starve the fetus of nutrients and oxygen while putting the mother at serious risk of severe anemia. It is overwhelmingly caused by Plasmodium falciparum, which has evolved a specific protein that locks infected red blood cells onto the placental lining. In regions of sub-Saharan Africa and parts of Southeast Asia and Latin America where malaria is common, placental malaria remains one of the leading preventable causes of poor pregnancy outcomes, contributing to low birth weight, preterm delivery, stillbirth, and maternal death.

How Parasites Hijack the Placenta

The placenta is normally off-limits to most malaria parasites circulating in the bloodstream. But P. falciparum has a workaround. Infected red blood cells display a large surface protein called VAR2CSA, which binds with high affinity to a sugar molecule called chondroitin sulfate A (CSA) that decorates the surface of the placental lining, known as the syncytiotrophoblast.¹ This binding is remarkably specific. The CSA is carried on a particular protein scaffold on the placental surface called syndecan-1, which acts as the main docking station for VAR2CSA-mediated attachment.²

The binding affinity between VAR2CSA and CSA is extremely tight, in the low-nanomolar range, meaning even a small number of infected cells can latch on firmly and resist being swept away by blood flow.³ Once anchored, infected red blood cells pile up in the intervillous space, the blood-filled channels between the finger-like projections of the placenta where nutrient and gas exchange happens. This sequestration is what distinguishes placental malaria from ordinary malaria infection during pregnancy. It is not just that a pregnant woman has malaria; it is that parasites have colonized the organ her baby depends on.

What Happens to the Placenta Itself

The accumulation of parasitized red blood cells triggers a cascade of damage to placental tissue. Studies using human placental explants show that P. falciparum infection significantly damages the trophoblast layer, which is the outer barrier of the placental villi responsible for nutrient transport. Researchers have documented increased cell death markers along with structural problems including abnormal clumping of cell nuclei (syncytial knots), fibrin deposits, areas of tissue death, detachment of the trophoblast from its underlying stroma, and disorganization of the collagen fibers that give villi their structural integrity.⁴

The body’s immune response to these parasites makes things worse in some ways. Monocytes and other immune cells flood into the intervillous space, releasing inflammatory molecules. Placental levels of the inflammatory signaling molecule TNF-alpha are strongly correlated with parasite density and with the number of immune cells infiltrating the placenta. Elevated TNF-alpha in the placenta is also linked to lower birth weight and febrile symptoms in the mother.⁵ This inflammation, while aimed at fighting the parasite, disrupts placental blood flow and the transfer of oxygen and nutrients to the growing fetus.⁶

Dangers to the Mother

The most common serious consequence for the mother is severe anemia. Malaria destroys red blood cells directly during the parasite’s reproductive cycle, and the inflammatory response in the placenta further suppresses red blood cell production. A large meta-analysis of studies across sub-Saharan Africa found that about 39% of women with placental malaria had maternal anemia.⁷ In areas where malaria transmission is high, full-blown cerebral malaria and other severe syndromes are relatively uncommon in pregnant women because most have some prior immunity. But severe anemia is frequent and can be life-threatening, especially when combined with blood loss during delivery.⁸

The danger is greatest during a woman’s first pregnancy. In high-transmission settings, women gradually build up immunity to the placental-binding form of malaria over successive pregnancies, because their immune systems learn to recognize VAR2CSA. Antibodies against CSA-binding parasites increase with each pregnancy and across trimesters.¹ This explains a pattern that has long puzzled observers: malaria in pregnancy tends to be worst the first time around and less severe in later pregnancies. Women in low-transmission areas, who have had fewer exposures overall, remain vulnerable regardless of how many pregnancies they have had.

Consequences for the Baby

The downstream effects on the fetus are extensive. By choking off nutrient delivery and oxygen supply, placental malaria can restrict fetal growth and trigger early delivery. Pooled data from sub-Saharan Africa put the rate of low birth weight among babies born to women with placental malaria at about 13%, preterm delivery at roughly 11%, and small-for-gestational-age babies at about 18%.⁷ Stillbirth is less common but still elevated; one study found an odds ratio of about 3.8, meaning the risk was nearly four times higher compared to pregnancies without placental malaria.⁹

Research in animal models has helped clarify the mechanism. Parasite sequestration in the placenta directly reduces fetal weight, but the effect is also driven by the immune imbalance it causes. In the placenta of infected mice, levels of the pro-inflammatory molecule IL-17 go up while the anti-inflammatory molecule IL-10 goes down. Both shifts independently contribute to reduced fetal weight, meaning the damage is partly from the parasites themselves and partly from the mother’s own inflammatory response going off-balance.¹⁰

Congenital malaria, in which the parasite crosses the placenta and infects the newborn, occurs in roughly 7% of cases of placental malaria in sub-Saharan Africa based on pooled estimates.⁷

Long-Term Effects on Children’s Development

The harm does not necessarily end at birth. A prospective study that followed mother-child pairs in Benin found that prenatal malaria exposure had measurable effects on children’s brain development lasting into early childhood. Malaria during pregnancy was associated with impaired gross motor development at age one. By age six, children whose mothers had malaria during pregnancy scored lower on cognitive assessments, with infections later in pregnancy and higher parasite densities at delivery showing stronger negative effects.¹¹

There is also evidence that in utero exposure to malaria antigens can alter the developing fetal immune system. A birth cohort study in Kenya found that a substantial proportion of newborns who had been exposed to malaria through the placenta showed signs of immune tolerance rather than immune readiness. Among exposed newborns whose immune cells appeared unresponsive to malaria antigens, about half showed signs of active anergy, meaning their immune cells were alive but deliberately suppressed. This tolerance could make these children more vulnerable to malaria infections later in life.¹² The fetal immune system appears to be learning the wrong lesson: instead of priming itself to fight malaria, it is being conditioned to tolerate it.¹³

When the Parasite Is Not P. falciparum

Most discussion of placental malaria centers on Plasmodium falciparum because its VAR2CSA-mediated binding to the placenta is so specific and aggressive. But Plasmodium vivax, the other major human malaria parasite, can also cause problems during pregnancy, though through a different and less well-understood mechanism. P. vivax-infected red blood cells can bind CSA, but at roughly one-tenth the level of P. falciparum, and actual accumulation of P. vivax parasites in the placenta is rarely observed.¹⁴

Histological examination of placentas from women with P. vivax monoinfection has found parasitized red blood cells in the intervillous space in some cases, but without the characteristic inflammatory cell infiltration or hemozoin pigment deposition seen in P. falciparum infections.¹⁵ Yet P. vivax during pregnancy is still clearly associated with poor outcomes. A prospective cohort in the Brazilian Amazon found that P. vivax infections in the first trimester increased the odds of premature birth about eightfold and the odds of low birth weight about fourfold. Placentas from infected women showed increased syncytial nuclear aggregates, fibrin deposits, and immune cell infiltration compared to uninfected women.¹⁶ The leading hypothesis is that the intense inflammatory surges during P. vivax fever episodes may be enough to impair fetal growth and cause anemia even without heavy placental sequestration.¹⁴

Why Diagnosis Is Tricky

One of the frustrating aspects of placental malaria is that standard blood tests during pregnancy often miss it. Parasites sequestered in the placenta may not show up in a blood sample drawn from the mother’s arm. Comparative studies at delivery have consistently shown a dramatic gap in detection rates. In one study, peripheral blood films detected infection in only about 8% of cases, while placental histology picked it up in over 60%.¹⁷ Another found peripheral blood films had a sensitivity of just 47% compared to 91% for placental histology.¹⁸

The problem is that placental histology can only be done after delivery, which makes it useless for guiding treatment during pregnancy. Researchers have been exploring whether blood biomarkers in the mother could flag occult placental infections. A case-control study in Malawi found that a scoring system combining clinical information with blood biomarkers (drops in certain growth factors and rises in an inflammation marker) could identify hidden placental infections with reasonable accuracy.¹⁹ This line of research is still early-stage, but it highlights how much placental malaria is missed by conventional screening.

Prevention Strategies That Exist Today

Because diagnosis during pregnancy is unreliable, the main approach in malaria-endemic countries is presumptive prevention. The World Health Organization recommends intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP), in which pregnant women receive doses of an antimalarial drug at scheduled antenatal visits regardless of whether they test positive. This strategy has been a backbone of maternal malaria prevention for over two decades. Insecticide-treated bed nets (ITNs) are the other pillar. A systematic review of randomized trials found that in Africa, ITNs increased average birth weight by about 55 grams, reduced low birth weight by roughly a quarter, and cut miscarriages and stillbirths by about a third in the first few pregnancies. Placental parasitemia was reduced by about 23% across all pregnancies.²⁰

Combining both strategies appears to be more effective than either alone. A cost-effectiveness analysis in Nigeria found that using IPTp-SP together with ITNs averted more disability-adjusted life years than IPTp-SP alone, and was cost-effective even by conservative standards.²¹

The growing concern, however, is drug resistance. Parasite resistance to sulfadoxine-pyrimethamine has been rising across Africa, and the effectiveness of IPTp-SP at preventing malaria infection drops substantially in areas with high resistance. In high-resistance areas, parasite recurrence rates after treatment are many times higher than in low-resistance areas.²² An updated meta-analysis confirmed this trend but noted something puzzling: even in areas where SP barely clears malaria infections anymore, IPTp-SP still seems to reduce low birth weight, possibly through anti-inflammatory or growth-promoting effects unrelated to killing parasites.²³ Regardless, alternative preventive drugs are urgently needed.

Vaccine Efforts Targeting VAR2CSA

Because VAR2CSA is the protein that lets parasites stick to the placenta, it is the leading target for a vaccine specifically designed to prevent placental malaria. The idea is to generate antibodies that block the VAR2CSA-CSA interaction before infected red blood cells can anchor themselves. Two vaccine candidates based on fragments of VAR2CSA have entered early human testing.²⁴

One of these, called PAMVAC, was tested in a first-in-human trial in healthy adults who had never had malaria. Volunteers received three doses of the vaccine at different doses and with different immune-boosting additives. The trial was primarily designed to check safety and immune responses rather than to measure protection against infection.²⁵ A challenge with VAR2CSA-based vaccines is the protein’s natural diversity. Different parasite strains carry different versions of VAR2CSA, and antibodies raised against one variant may not fully recognize another.¹ Getting a vaccine to provide broad cross-strain protection remains one of the biggest hurdles. Still, the fact that women naturally build up protective immunity over multiple pregnancies is proof of concept that the immune system can learn to block placental parasites.

HIV Co-infection and Compounding Risks

In many regions where placental malaria is common, HIV is also prevalent, and the two infections interact in damaging ways. HIV weakens the immune control that normally keeps malaria parasites in check, and malaria-driven inflammation can accelerate HIV replication. In the placenta specifically, co-infection with malaria and HIV is associated with more intense immune activation. Markers of neutrophil activation, including myeloperoxidase, are significantly elevated in placental blood from women with placental malaria and are even higher when HIV co-infection is present. These markers track with parasite density and the accumulation of immune cells carrying malaria pigment.²⁶ The amplified inflammatory environment in co-infected placentas likely worsens the tissue damage and nutrient delivery problems described above, though disentangling the separate contributions of each infection remains difficult.

Who Is Most at Risk

Certain groups face a disproportionate burden. Women in their first pregnancy are the most vulnerable in high-transmission areas, because they have not yet developed antibodies against the placental-binding form of the parasite.⁸ But the risk is not purely biological. Limited access to antenatal care, young maternal age, and poverty are all consistently associated with higher rates of placental malaria and anemia.²⁷ Women who cannot get to a clinic for IPTp-SP doses or who cannot afford a bed net bear the greatest burden. Adolescent mothers face a double disadvantage: they are more likely to be in their first pregnancy and less likely to access healthcare.

In low-transmission settings, including areas on the fringes of malaria elimination, the picture shifts. Women there have had fewer prior exposures and lack the partial immunity that protects multigravid women in high-transmission zones. Any pregnancy, not just the first, carries significant risk if malaria is acquired. This is particularly relevant for travelers to endemic areas and for women in regions where malaria is re-emerging due to climate change or disrupted control programs.

Placental Changes From P. vivax Without Classic Sequestration

The distinction between P. falciparum and P. vivax placental changes is worth understanding in more detail, because it has practical implications in regions like South and Central America and parts of Asia where P. vivax predominates. Researchers in Brazil developed a scoring system to distinguish placentas affected by P. vivax from unaffected ones, based on three features: increased clumping of syncytial nuclei, thickening of the placental barrier, and the presence of immune cells. These pathological changes were significantly more common in placentas from women who had been exposed to P. vivax during pregnancy, even though the classic picture of parasites packed into the intervillous space was largely absent.²⁸ This means that a placenta can sustain meaningful damage from malaria even without the heavy parasite accumulation that defines classic P. falciparum placental malaria. In practice, this undermines any assumption that P. vivax during pregnancy is benign simply because it does not sequester heavily in the placenta.